CN116813621A - 9h嘌呤类化合物及其药物组合物和用途 - Google Patents
9h嘌呤类化合物及其药物组合物和用途 Download PDFInfo
- Publication number
- CN116813621A CN116813621A CN202310676552.3A CN202310676552A CN116813621A CN 116813621 A CN116813621 A CN 116813621A CN 202310676552 A CN202310676552 A CN 202310676552A CN 116813621 A CN116813621 A CN 116813621A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- hydrogen
- heteroatoms
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 title description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- -1 9H purine compound Chemical class 0.000 claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 22
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims abstract description 18
- 201000011510 cancer Diseases 0.000 claims abstract description 10
- 230000005764 inhibitory process Effects 0.000 claims abstract description 10
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 125000005842 heteroatom Chemical group 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000010572 basal-like breast carcinoma Diseases 0.000 claims description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 5
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 3
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 229940077388 benzenesulfonate Drugs 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 3
- 229940050410 gluconate Drugs 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229940049964 oleate Drugs 0.000 claims description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 claims description 2
- 229940080296 2-naphthalenesulfonate Drugs 0.000 claims description 2
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 claims description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 claims description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 2
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- RGHNJXZEOKUKBD-KLVWXMOXSA-N L-gluconic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-KLVWXMOXSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 229920002230 Pectic acid Polymers 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 229940050390 benzoate Drugs 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 2
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 claims description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 claims description 2
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 2
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 claims description 2
- 229930195712 glutamate Natural products 0.000 claims description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000686 lactone group Chemical group 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 125000005341 metaphosphate group Chemical group 0.000 claims description 2
- 229940095102 methyl benzoate Drugs 0.000 claims description 2
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 239000011230 binding agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 claims 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 239000004088 foaming agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000003094 microcapsule Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000003204 osmotic effect Effects 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229940049953 phenylacetate Drugs 0.000 claims 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 64
- 238000002360 preparation method Methods 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 230000002503 metabolic effect Effects 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 210000004556 brain Anatomy 0.000 abstract description 4
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 4
- 208000003174 Brain Neoplasms Diseases 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 206010027476 Metastases Diseases 0.000 abstract description 2
- 230000009702 cancer cell proliferation Effects 0.000 abstract description 2
- 230000009401 metastasis Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 29
- 230000002829 reductive effect Effects 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 17
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000007858 starting material Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000758 substrate Substances 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108091007914 CDKs Proteins 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 5
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 5
- 102000016736 Cyclin Human genes 0.000 description 5
- 108050006400 Cyclin Proteins 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000006820 DNA synthesis Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- DLPIYBKBHMZCJI-WBVHZDCISA-N (2r,3s)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CC)[C@@H](C)O)=NC=1NCC1=CN=C(C)C=C1C DLPIYBKBHMZCJI-WBVHZDCISA-N 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000010190 G1 phase Effects 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 230000018199 S phase Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- XDHPEJLTRTYRFY-UHFFFAOYSA-N n,4,6-trimethylpyridin-3-amine Chemical compound CNC1=CN=C(C)C=C1C XDHPEJLTRTYRFY-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- QUIMJTKRVOBTQN-UHFFFAOYSA-N (2,4-dimethylphenyl)methanol Chemical compound CC1=CC=C(CO)C(C)=C1 QUIMJTKRVOBTQN-UHFFFAOYSA-N 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 2
- UNRIYCIDCQDGQE-UHFFFAOYSA-N 6-chloro-2-fluoro-7h-purine Chemical compound FC1=NC(Cl)=C2NC=NC2=N1 UNRIYCIDCQDGQE-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 description 2
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 229940013204 fadraciclib Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000016507 interphase Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- YSPJZEMKUGOFNG-UHFFFAOYSA-N n-[(4,6-dimethylpyridin-3-yl)methyl]-2-fluoro-7h-purin-6-amine Chemical compound C1=NC(C)=CC(C)=C1CNC1=NC(F)=NC2=C1N=CN2 YSPJZEMKUGOFNG-UHFFFAOYSA-N 0.000 description 2
- DEMQDYYIDUWXIF-UHFFFAOYSA-N n-[(4,6-dimethylpyridin-3-yl)methyl]-2-fluoro-9-propan-2-ylpurin-6-amine Chemical compound N1=C(F)N=C2N(C(C)C)C=NC2=C1NCC1=CN=C(C)C=C1C DEMQDYYIDUWXIF-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- RETJKTAVEQPNMH-UHFFFAOYSA-N 2-chloro-4,6-dimethylpyridine-3-carbonitrile Chemical compound CC1=CC(C)=C(C#N)C(Cl)=N1 RETJKTAVEQPNMH-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- NJRXVEJTAYWCQJ-UHFFFAOYSA-L 2-mercaptosuccinate Chemical compound OC(=O)CC([S-])C([O-])=O NJRXVEJTAYWCQJ-UHFFFAOYSA-L 0.000 description 1
- OCYMJCILWYHKAU-UHFFFAOYSA-N 4,6-dimethyl-2-oxo-1h-pyridine-3-carbonitrile Chemical compound CC1=CC(C)=C(C#N)C(O)=N1 OCYMJCILWYHKAU-UHFFFAOYSA-N 0.000 description 1
- BZIDYPIJVCEUIB-UHFFFAOYSA-N 4,6-dimethylpyridine-3-carbonitrile Chemical compound CC1=CC(C)=C(C#N)C=N1 BZIDYPIJVCEUIB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 description 1
- 102100033245 Cyclin-dependent kinase 16 Human genes 0.000 description 1
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 230000035519 G0 Phase Effects 0.000 description 1
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 description 1
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000006449 cycloalkyl cyclopropyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了9H嘌呤类化合物及其药物组合物和用途,属于化学医药领域。本发明提供一种如通式(I)所示结构的9H嘌呤类化合物,该类化合物在治疗由高表达CDK2介导的疾病中具有优异的药效学性能和高的代谢稳定性,该化合物或其药学上可接受的盐适合用于制备治疗癌症药物,具有优异的癌细胞增殖抑制作用,尤其适合制备癌症脑转移或原发性脑癌药物中的用途。
Description
技术领域
本发明属于化学医药领域,具体涉及9H嘌呤类化合物及其药物组合物和用途。
背景技术
目前广为人知的常见癌症疾病如乳腺癌,肺癌,肺癌,结直肠癌,前列腺癌,胃癌,肝癌和子宫癌以外,还存在很多新增或已有的罕见癌症。细胞周期是指连续分裂的细胞从上一次分裂完成开始,到下一次分裂完成为止所经历的连续动态过程。细胞周期可分为两个阶段,即细胞分裂间期和有丝分裂期(M期)。其中分裂间期以DNA合成为标志,可细分为四个阶段。处于DNA合成前期的G1期,该过程主要进行RNA与蛋白质如酶蛋白和结构蛋白的合成,并逐步激活大量与DNA合成有关的酶,此外G1期占据了整个周期的大部分时间。在DNA集中合成的S期内,需要首先启动DNA复制,具体复制所需时间依据整体基因组的情况决定,期间同时进行组蛋白和非组蛋白的合成工作,后期将复制的DNA与组蛋白分子组合形成核小体,S期内所复制得到的DNA数量为G0期细胞的2倍细胞周期的调控是多因素参与的过程,研究表明,cyclin、CDKs和CDKs抑制物(CKIs)共同参与调控。
Cyclin是细胞周期进程机制的关键组成部分,通过结合与激活它们的伙伴——CDKs,以复合物的形式完成与细胞内对应底物蛋白的结合。CDKs为参与细胞周期调控的主要物质,其主要作用是与cyclin形成复合物后,并在特定条件下对不同底物如Rb蛋白等实现磷酸化作用。
CDK2属于丝/苏氨酸蛋白激酶家族,与CDK1,CDK4和CDK6激酶一同参与细胞周期的调控。其他CDK如CDK3,CDK5,CDK7,CDK8,CDK9,CDK12等则侧重于推动蛋白转录和翻译过程,其中也存在调控整体细胞周期运转的上游激酶,如CDK7等。由上述可知,CDK2贯穿细胞周期G1期与S期的DNA合成阶段,并在两个阶段先后与不同的cyclin结合而效果显著。CDK2除了对细胞生长有调控作用,还可参与细胞分化在细胞凋亡方面,CDK2的作用也不容小觑。有趣的是,它对细胞凋亡存在双向调节功能。
在CDK2靶点的早期研究中发现,之前的候选药物存在严重的脱靶效应,因此研究热度逐渐下降。但通过对CDK2在各个信号通路中的分子机制研究发现,特异性抑制CDK2可以有效阻遏相关细胞异常增生。CDK2抑制剂针对常见的乳腺癌化疗药阿霉素也可起到协同作用。此外,该类型小分子抑制剂在器官移植过程中可通过调节淋巴细胞在特定时期的反应性,从而一定程度上起到免疫抑制作用。
总之,CDK2抑制剂具有针对电离辐射或诱导DNA损害的化疗药剂敏化肿瘤细胞的潜力,具有诱导选择性杀死肿瘤细胞以及在具有DNA损害反应缺陷的肿瘤细胞亚群(subsets)中诱导合成致死的潜力。
发明内容
发明要解决的问题
为了解决上述技术问题,本发明人发现了一类新的9H嘌呤类衍生物,其在保障药效学性能的情况下还具有良好的代谢稳定性。
进一步地,本发明提供了具有通式(I)的化合物或其药学上可接受的盐,药物组合物以及用途。
用于解决问题的方案
本发明提供如下方案:
一种具有通式(I)的9H嘌呤类化合物或其药学上可接受的盐:
其中:
R1选自:其中,R3和R4各自独立地为氢或C1-8烷基(其中包含不同光学异构构型,分为S或R构型),或者R3和R4与其所连接的原子一起形成含0-3个杂原子的4-6元环,杂原子为O或N;R5和R6各自独立选自氢、C1-8烷基、三氟甲基、C3-6环烷基(其中包含不同光学异构构型,分为S或R构型),或者R5和R6与其所连接的原子形成含有一个O和0-2个杂原子的4-6元环或内酯环,杂原子为O或S;R7和R8各自独立选自氢、C1-8烷基,或者R7和R8与其所连接的杂原子一起形成含有0-3个杂原子的3-6元环,杂原子为O或S;
n1为2-4;n2为0-3;
R2选自:其中,X1、X5和X9各自独立地为CH2、NH或O;X2、X3、X4、X6、X7和X8各自独立地为CH或N;R为H、C1-3烷基;R9和R10选自氢、C1-3烷基、含1-2个N原子的含氮芳杂环或脂杂环、NR’R”或NHCOR”’,R’、R”、R”’各自独立地选自氢或甲基;R11和R12各自独立地为氢、卤素、C1-3烷基,或者R11和R12与其所连接的原子一起形成含有0-3个杂原子的饱和3-6元环,杂原子为O或N;R13为氢、卤素、C1-3烷基或C5-6环烷基、/>其中,X10和X11各自独立地为CH或N,R16为C1-5烷基或含有0-3个杂原子的饱和4-6元环,杂原子为O或N;R14为氢、卤素、C1-3烷基或C5-6环烷基;R15为氢、卤素、C1-3烷基、含有0-3个杂原子的饱和4-6元环;
R17选自:其中,R18、R19各自独立地为H、C1-3烷基,或R18和R19与其所连接的原子一起形成C3-6环烷基;R20和R21为C1-3烷基;R22为氢或C1-2烷基。
在本发明的一种实施方式中,所述的化合物或其药学上可接受的盐中,
R1为R3和R4各自独立地为氢或C1-8烷基,其中包含不同光学异构构型,分为S或R构型;或R3和R4与其所连接的原子一起形成环A;环A为C3-6环烷基或含有一个选自O或N的杂原子的饱和4-6元杂环;n1为2、3、4;
或者,R1为X选自CH2、O或S;R5和R6独立选自氢、C1-C8烷基、其中包含不同光学异构构型,分为S或R构型;或R5和R6与其所连接的原子一起形成环B;环B为含有一个选自O或S的杂原子的饱和5-6元杂环;n2为0、1、2、3;
或者,R1为R7和R8为C1-8烷基。
在本发明的一种实施方式中,所述的化合物或其药学上可接受的盐进一步可选,
R1为X选自O或S;R5和R6独立选自氢、甲基、其中包含不同光学异构构型,分为S或R构型;n2为0;
或者,R1为R7和R8为甲基。
在本发明的一种实施方式中,所述的化合物或其药学上可接受的盐中,
R2进一步优选自
其中,X1、X5和X9各自独立地选自NH或O,X2优选N,X3优选CH,X6、X7和X8各自独立地为CH或N。
在本发明的一种实施方式中,R9和R10选自氢、甲基、含1-2个N原子的含氮芳杂环或脂杂环。
在本发明的一种实施方式中,R13为C1-3烷基,C5-6环烷基,其中,X10和X11各自独立地为CH;R16为C1-5烷基或含有一个选自O或N的杂原子的饱和4-6元杂环。
在本发明的一种实施方式中,所述的化合物或其药学上可接受的盐中,R17进一步优选自其中,R18、R19为C1-3烷基或R18和R19与其所连接的原子一起形成C3-6环烷基。
在本发明的一种实施方式中,所述的化合物或其药学上可接受的盐中,R17可具体选自:C1-5链烷基、C3-6环烷基。其中,C1-5链烷基包括甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基、异戊基等;C3-6环烷基环丙基、环丁基、环戊基。
在本发明的一种实施方式中,所述的化合物或其药学上可接受的盐具体可选自:
本发明还提供一种药物组合物,其包含上述9H嘌呤类化合物或其药学上可接受的盐,以及任选地药学上可接受的赋形剂剂、稀释剂或载体。
本发明还提供上述9H嘌呤类化合物或其药学上可接受的盐在制备用于治疗和/或预防癌症、结直肠癌(CRC)、非小细胞肺癌(NSCLC)、膀胱癌、基底样乳腺癌(BLBC)、胰腺癌(PC)、骨髓增生异常综合征(MDS)、B细胞慢性淋巴性白血病(B-CLL)、急性髓性白血病(AML)和细菌以及HIV-1病毒感染的药物中的用途。
在本发明的一种实施方式中,其中所述药物用于治疗和/或预防选自头部、颈部、眼睛、口腔、咽喉、食道、支气管、喉、咽、胸、骨、肺、结肠、直肠、胃、前列腺、膀胱、子宫、子宫颈、乳房、卵巢、睾丸或其他生殖器官、皮肤、甲状腺、血液、淋巴结、肾、肝、膜腺、脑、中枢神经系统、实体瘤和血液传播肿瘤的癌症的疾病。
本发明还提供上述9H嘌呤类化合物或其药学上可接受的盐在制备用于预防或治疗对抑制CDK2敏感的肿瘤药物中的用途。
本发明的有益效果:
本发明提供通式(I)9H嘌呤类化合物,在治疗由高表达CDK2介导的疾病中具有优异的药效学性能和高的代谢稳定性,该化合物或其药学上可接受的盐适合用于制备治疗癌症药物,本发明的化合物具有优异的癌细胞增殖抑制作用,尤其适合制备癌症脑转移或原发性脑癌药物中的用途,在一些具体实施方式中,本发明的化合物特别适合制备脑部肿瘤放疗辅助药物。
具体实施方式
本发明人在研究CDK2抑制剂的过程中发现了一类新的9H嘌呤类衍生物,对细胞周期蛋白表达水平过高及CDK2表达水平过高具有良好的抑制作用,为CDK2介导的疾病提供一种治疗方案,预期此类抑制剂具有良好的开发前景。
在本发明中C1-8烷基是指具有1至8个碳原子的直链或支链的单价饱和烃基,其实例包括,但不限于甲基、乙基、1-丙基、2-丙基、1-丁基、2-甲基-1-丙基、2-丁基、2-甲基-2-丙基、叔丁基、1-己基、2-乙基丁基等。
C3-6环烷基是指3至6个碳原子的环烷基,其实例包括,但不限于环丁基、环戊基、环己基、烷基取代环烷基;
含氮芳杂环是指:成环的原子除碳原子外,还至少含有一个氮原子,其实例包括,但不限于吡咯、咪唑、噻唑等。
脂杂环是指:含有多种脂肪基或脂肪族基团的杂环化合物。这些化合物的结构中包含了脂肪基和多种杂原子如N、O、S等,它们结合在一起形成了环状的分子结构。实例中包括但不限于哌嗪、哌啶、噻吩等。
表示取代基从该处连接。
在本发明中,“给药”或“给予”个体化合物是指向需要治疗的个体提供本发明的化合物。
如本文使用的术语“药学可接受的”是指在合理的医学范围内,适用于与人和其他哺乳动物的组织接触而没有过度毒性、剌激、过敏反应等,并且有合理的利益/风险比的组分。
如本文使用的术语“疾病”是指损害或干扰细胞、器官或组织的正常功能的任何病症或紊乱。
如本文所使用的术语“抑制剂”是指化合物或试剂具有抑制靶向蛋白或多肽的生物学功能的能力,例如通过抑制蛋白质或多肽的活性或表达。
在本发明中“任选”或“任选地”是指随后描述的事件或情况可能发生或可能不发生,该描述包括发生所述事件或情况和不发生所述事件或情况。例如,乙基“任选”被卤素取代,指乙基可以是未被取代的(CH2CH3)、单取代的(如CH2CH2F)、多取代的(如CHFCH2F、CH2CHF2等)或完全被取代的(CF2CF3)。本领域技术人员可理解,对于包含一个或多个取代基的任何基团,不会引入任何在空间上不可能存在和/或不能合成的取代或取代模式。
在整个本说明书中提到的“实施方式”或“实施方案”或“在另一实施方案中”或“在某些实施方案中”或“在本申请的部分实施方式中”意指在至少一实施方案中包括与该实施方案所述的相关的具体参考要素、结构或特征。因此,在整个说明书中不同位置出现的短语“在一实施方案中”或“在实施方案中”或“在另一实施方案中”或“在某些实施方案中”或“在本申请的部分实施方式中”不必全部指同一实施方案。此外,具体要素、结构或特征可以任何适当的方式在一个或多个实施方案中结合。
除非本申请中另外要求,在整个说明书和其后的权利要求书中,词语“包括(comprise)”及其英文变体例如“包括(comprises)”和“包括(comprising)”应解释为开放式的、含括式的意义,即“包括但不限于”。
应当理解,在本申请说明书和附加的权利要求书中用到的单数形式的冠词“一”(对应于英文“a”、“an”和“the”)包括复数的对象,除非文中另外明确地规定。
本发明的化合物可以含有一个或多个不对称中心,并且因此作为外消旋物和外消旋混合物、单一对映体、单独的非对映体和非对映体混合物出现。这些化合物的所有此类异构体形式均明确地包括在本发明中。本发明的化合物还可以表现为多种互变异构形式,在此情况下,本发明明确地包括本文所述的化合物的所有互变异构形式。此类化合物的所有此类异构体形式包括在本发明中。本文所述的化合物的所有结晶形式明确地包括在本发明中。
本发明提供一种9H嘌呤类衍生物、它们的制备方法、含有它们的药物组合物、以及它们的治疗用途。该化合物作为CDK2抑制剂,并且药效学性能更好、代谢稳定性更高。
<化合物或其药学上可接受的盐>
根据本发明的第一方面,提供式(I)化合物或其药学上可接受的盐:
本发明还包含式(I)化合物在药学上可接受的盐。术语“药学上可接受的盐”是指保留母体化合物的生物有效性和性质的相对无毒的本发明化合物的酸加成盐。所述酸加成盐为本发明(I)化合物与合适的无机酸或者有机酸形成的盐,这些盐可在化合物最后的分离和提纯过程中制备,或者可用纯化的式(I)化合物以其游离碱形式与适宜的有机酸或者无机酸进行反应来制备。本发明所述的药学上可接受的盐为无机盐或有机盐,无机盐包括乙酸盐、己二酸盐、藻酸盐、精氨酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐、硫酸氢盐、亚硫酸氢盐、溴化物、丁酸盐、樟脑酸盐、樟脑磺酸盐、辛酸盐、氯化物、氯苯甲酸盐、柠檬酸盐、环戊烷丙酸盐、双葡萄糖酸盐、磷酸二氢盐、二硝基苯甲酸盐、十二烷基硫酸盐、乙磺酸盐、富马酸盐、甲酸盐、粘酸盐、半乳糖醛酸盐、葡萄糖庚酸盐、葡萄糖酸盐、谷氨酸盐、甘油磷酸盐、半琥珀酸盐、半硫酸盐、庚酸盐、己酸盐、马尿酸盐、盐酸盐、氢溴酸盐、氢碘酸盐、2-羟基乙磺酸盐、碘化物、羟乙基磺酸盐、异丁酸盐、乳酸盐、手L糖酸盐、苹果酸盐、马来酸盐、丙二酸盐、扁桃酸盐、偏磷酸盐、甲磺酸盐、甲基苯甲酸盐、磷酸一氢盐、2-萘磺酸盐、烟酸盐、硝酸盐、草酸盐、油酸盐、棕榈酸盐、果胶酸盐、过硫酸盐、苯乙酸盐、3-苯基丙酸盐、磷酸盐、膦酸盐、邻苯二甲酸盐,但这并不代表着限制。
在上述所提及的药物盐中,优选的药物盐包括乙酸盐、三氟乙酸盐、苯磺酸盐、柠檬酸盐、富马酸盐、葡萄糖酸盐、半琥珀酸盐、马尿酸盐、盐酸盐、氢溴酸盐、羟乙基磺酸盐、扁桃酸盐、葡甲胺盐、硝酸盐、油酸盐、膦酸盐、新戊酸盐、磷酸纳盐、硬脂酸盐、硫酸盐、磺基水杨酸盐、酒石酸盐、硫代苹果酸盐、甲苯磺酸盐和氨丁三醇盐,但这并不代表着限制。
特别优选盐酸盐、二盐酸盐、氢溴酸盐、马来酸盐、甲磺酸盐、磷酸盐、硫酸盐和琥珀酸盐。
本发明还提供了通式(I)化合物的制备方法,所述方法通过以下反应方案来实施:
方案1:
如反应式1所示,将化合物1与三氯氧磷通过卤代反应得到化合物2,化合物2与Zn粉/盐酸体系还原剂通过酸性条件下金属还原反应得到化合物3,化合物3在有机碱条件下与Raney Ni/H2与二碳酸二叔丁酯一锅煮法通过金属催化后得到的还原产物同时被叔丁氧羰基保护得到化合物4,化合物4与三氟乙酸反应脱去叔丁氧羰基保护基得到化合物5。
方案2:
本发明还涉及药物,其包含至少一种式I化合物和/或其药学上可接受的盐、溶剂化物和立体异构体,包括其以所有比例的混合物,和任选的赋形剂和/或稀释剂、载体。
本发明化合物适合在癌症治疗中作为用于哺乳动物,尤其是人类的药物活性成分。
本发明包括式I化合物和/或其药学上可接受的盐、互变异构体和立体异构体用于制备治疗或预防癌症的药物的用途。
本发明包括式I化合物和/或其药学上可接受的盐、互变异构体和立体异构体在用于治疗和/或预防癌症、结直肠癌(CRC)、非小细胞肺癌(NSCLC)、膀胱癌、基底样乳腺癌(BLBC)、胰腺癌(PC)、骨髓增生异常综合征(MDS)、B细胞慢性淋巴性白血病(B-CLL)、急性髓性白血病(AML)和细菌以及HIV-1病毒感染的药物中的用途的。
本发明还涵盖式I化合物和/或其药学上可接受的盐、互变异构体和立体异构体用于制备用于治疗或预防哺乳动物中的CDK2诱导的疾病或CDK2诱导的病症的药物的用途,其中在该方法中对需要这种治疗的患病哺乳动物给予治疗有效量的根据本发明的化合物。治疗量根据具体疾病而变化,并且可以由本领域技术人员确定无需过度努力。
本发明特别涉及式I化合物以及其药学上可接受的盐、互变异构体和立体异构体,包括其以所有比例的混合物,其用于抑制CDK2。
本发明式I化合物可用于治疗或预防的代表性癌症包括,但不限于,头部、颈部、眼睛、口腔、咽喉、食道、支气管、喉、咽、胸、骨、肺、结肠、直肠、胃、前列腺、膀胱、子宫、子宫颈、乳房、卵巢、睾丸或其他生殖器官、皮肤、甲状腺、血、液、淋巴结、肾、肝、膜腺、脑、中枢神经系统、实体瘤和血液传播肿瘤的癌症。
优选地,本发明涉及其中疾病是癌症的方法。
特别优选地,本发明涉及其中疾病是癌症的方法,其中与给药至少一种其他活性药物剂同时、顺序或交替给药。在本发明的一些实施方式中,本发明的方法也包括非治疗目的的方法。
下列实施例用于说明而非限定通式(I)化合物的合成方法。温度均为摄氏度。如果没有另外说明,所有的蒸发均在减压下进行。如果没有另外说明,否则试剂是自商业供货商购得且未经进一步纯化即使用。终产物、中间体和原料的结构通过标准分析方法确认,例如元素分析、光谱特征分析,例如MS、NMR。使用的缩写是本领域常规缩写,部分中间体购置盐城正驰生物科技有限公司。
实施例1:(2R,5S)5-((6-(((4 6-二甲基吡啶-3-基)甲基)氨基)9-异丙基-9H-嘌呤-2-yl)氨基)-2-庚醇
步骤1:2-氯-3-氰基-4,6-二甲基吡啶(a)的制备
室温条件下,向装有POCl3(51.70g,337.50mmol,5.0eq)的三颈瓶中分批加入3-氰基-4,6-二甲基-2-羟基吡啶(10.00g,67.50mmol,1.0eq),室温搅拌30min后升温回流反应2h。TLC点板监测原料反应完毕后,减压蒸除部分POCl3,残留物在低温搅拌状态下缓慢加水,淬灭残留的POCl3,大量类白色固体出现。加入NaOH水溶液(2.00mol/L,100mL)缓慢调节pH至中性,加入EA(250mL×3)萃取。合并有机相,无水Na2SO4干燥过夜,减压蒸除溶剂后得白色固体a(9.85g),收率为98.5%。该步产物不经纯化,直接投下一步。ESI-HRMS m/z:167.0314[M+H]+。
步骤2:4,6-二甲基-3-氰基吡啶(b)的制备
0℃条件下,向装有a(9.85g,59.31mmol,1.0eq)的三颈瓶中缓慢加入浓HCl(m/m:37%):EtOH:H2O=5:1:1(V/V/V)的混合溶剂220mL,分批加入Zn粉(4.66g,71.21mmol,1.2eq)。0℃下反应30min,转至室温反应24h,反应体系完全变澄清。TLC点板监测原料a反应完全后,冰浴下加NaOH水溶液(2.00mol/L,200mL)缓调pH至弱碱性,减压抽滤除去新生成的Zn(OH)2沉淀,滤液加EA(250mL×3)萃取,合并的有机相,无机盐无水Na2SO4干燥过夜,减压蒸除溶剂后得到淡黄色固体(b,9.72g),收率为98.7%。ESI-HRMS(m/z):133.5570[M+H]+;步骤3:叔丁基((4,6-二甲基吡啶-3-基)甲基)氨基甲酸酯(c)的制备
将装有b(9.72g,73.61mmol,1.0eq)的三颈瓶中加入MeOH溶剂(150mL),再依次加入Raney Ni(1.00g,10.0%(m/m)),Boc2O(19.32g,88.32mmol,1.2eq)和Et3N(13.00g,128.80mmol,1.8eq),氢气保护下回流反应至反应完全。TLC点板监测原料b反应完全后,在硅藻土助滤下减压抽滤除去金属催化剂Raney Ni。滤液减压蒸除溶剂后残留物经硅胶柱层析[洗脱剂:PE:EA=10:1(v/v)]分离纯化后得到近白色油状液体c(7.35g),收率为75.6%。ESI-HRMS(m/z):237.1633[M+H]+;
步骤4:(4,6-二甲基吡啶-3-基)甲胺(d)的制备
将装有c(7.35g,31.23mmol,1.0eq)的三颈瓶中加入DCM(128mL)溶清,0℃下缓慢滴加TFA(32.00mL,43.14mmol,1.3eq),0℃下反应2h后转至室温反应1h,最后升至35℃反应过夜。TLC点板监测原料c反应完全,减压蒸馏除去溶剂DCM和大量反应试剂TFA后得到黄色油状液体,是关键中间体d的三氟乙酸盐形式(7.75g),收率为99.8%。ESI-HRMS(m/z):137.1120[M+H]+;
步骤5:N-((4,6-二甲基吡啶-3-基)甲基)2-氟-9H-嘌呤-6-胺(e)的制备
向装有d(0.13g,0.95mmol,1.5eq)的三颈瓶中加入正丁醇(5mL)溶清,再加入Et3N(0.34g,3.33mmol,3.5eq),N2保护下于0℃加入2-氟-6-氯-9H-嘌呤(0.09g,0.50mmol,1.0eq)的正丁醇溶液,0℃反应1h,转至室温反应4h,最后升至100℃反应3h。TLC点板监测原料反应完全,减压蒸馏除去溶剂后,加水(50mL×1)加EA(50mL×3)萃取,合并有机相,饱和NaCl溶液(50ml×1)萃取,有机相被减压蒸除溶剂后残留物经硅胶柱层析[洗脱剂:DCM:MeOH=100:1(v/v)]分离纯化,得到白色固体B-3(0.10g),收率为70.4%。ESI-HRMS(m/z):272.1231[M+H]+;
步骤6:N-((4,6-二甲基吡啶-3-基)甲基)2-氟-9-异丙基-9H-嘌呤-6-胺(f)的制备
向装有e(0.10g,0.35mmol,1.0eq)的三颈瓶中加入无水DMF(5mL),再加入无水K2CO3(0.49g,3.50mmol,10.0eq),N2保护下于室温缓慢加入异丙基溴(0.30g,2.40mmol,6.85eq),室温反应24h。TLC点板监测原料e反应完全,加水(200mL×1)加EA(250mL×3)萃取,合并有机相,饱和NaCl溶液(250mL×3)萃取。无水Na2SO4干燥过夜,减压蒸除溶剂后得到黄色油状液体f(0.10g),收率为95.8%。ESI-HRMS(m/z):315.1756[M+H]+;
步骤7:(2R,5S)5-((6-(((4 6-二甲基吡啶-3-基)甲基)氨基)9-异丙基-9H-嘌呤-2-yl)氨基)-2-庚醇的制备
向装有f(0.10g,0.33mmol,1.0eq)的微波反应瓶中加入1,2-丙二醇(2mL)溶清,再加入DIPEA(0.20g,1.34mmol,4.1eq)做碱,最后加入(2R,5S)-5-胺-2-庚醇(0.05g,0.50mmol,1.5eq)。放入微波反应器中,设置反应温度为150℃,反应20min。TLC点板监测发现原料d和f反应完全,加水(50mL×1)加EA(50mL×3)萃取,合并有机相,饱和NaCl溶液(250mL×1)萃取。有机相经减压蒸馏除去有机相溶剂后,残留物经硅胶板层析[展开剂:DCM:MeOH=20:1(v/v)]分离纯化得到化合物(0.11g),收率为84.0%。
ESI-HRMS(m/z):426.2931[M+H]+
1HNMR(400MHz,Methanol-d4)δ:8.30(s,1H),7.79(s,1H),7.13(s,1H),4.74(s,2H),4.61(h,J=6.9Hz,1H),3.89(dt,J=9.8,4.1Hz,1H),3.83(d,J=6.1Hz,1H),3.76(q,J=6.0Hz,2H),2.46(s,3H),2.39(s,3H),1.69(dtd,J=14.7,7.4,3.8Hz,1H),1.55(s,3H),1.53(s,3H),1.41(m,J=7.1Hz,2H),1.45(m,J=7.0Hz,2H),1.28(d,J=4.7Hz,1H),1.15(s,1H),1.12(s,3H),0.93(q,J=6.2,4.9Hz,3H).
除了用相应反应化合物替换实施例1中(2R,5S)-5-胺-2-庚醇,以和实施例1相同的方法合成以下化合物:
/>
实施例10:(2R,3S)-3-((6-((2,4二甲基苯基)氧)-9-异丙基-9H-嘌呤-2-基)氨基)-2-庚醇
步骤1:(6)-(2,4-二甲基苯基)氧-2-氟-9H-嘌呤(g)的制备
向装有(2,4-二甲基苯基)甲醇(0.13g,0.95mmol,1.9eq)的三颈瓶中加入正丁醇(5mL)溶清,再加入DIPEA(0.34g,3.33mmol,6.7eq),N2保护下于0℃加入2-氟-6-氯-9H-嘌呤(0.09g,0.50mmol,1.0eq)的正丁醇溶液,0℃反应1h,转至室温反应4h,最后升至90℃反应3h。TLC点板监测两个原料反应完全,减压蒸馏除去溶剂后,加水(50mL×1)加EA(50mL×3)萃取,合并有机相,饱和NaCl溶液(50mL×1)萃取,有机相被减压蒸除溶剂后残留物经硅胶柱层析[洗脱剂:DCM:MeOH=100:1(v/v)]分离纯化,得到淡黄色固体g(0.10g),收率为73.1%。ESI-HRMS m/z:273.1135[M+H]+
步骤2:6-((2,4-二甲基苯基)氧-2-氟-9-异丙基-9H-嘌呤(h)的制备
向装有g(0.10g,0.35mmol,1.0eq)的三颈瓶中加入无水DMF(5mL),再加入无水K2CO3(0.49g,3.50mmol,10.0eq),N2保护下于室温缓慢加入异丙基溴(0.30g,2.40mmol,6.8eq),室温反应24h。TLC点板监测原料g反应完全,加水(50mL×1)加EA(50mL×3)萃取,合并有机相,饱和NaCl溶液(50mL×3)萃。无水Na2SO4干燥过夜,减压蒸除溶剂后得到黄色油状液体h(0.10g),收率为90.9%。ESI-HRMS m/z:315.1628[M+H]+
步骤3:(2R,3S)-3-((6-((2,4二甲基苯基)氧)-9-异丙基-9H-嘌呤-2-基)氨基)-2-庚醇的制备
向装有h(0.10g,0.37mmol,1.0eq)的微波反应瓶中加入1,2-丙二醇(2mL)溶清,再加入DIPEA(0.20g,1.34mmol,3.6eq)做碱,最后加入(2R,5S)-5胺-2-庚醇(0.05g,0.50mmol,1.5eq)。放入微波反应器中,设置反应温度为150℃,反应20min。TLC点板监测发现原料h反应完全,加水(50mL×1)加EA(50mL×3)萃取,合并有机相,饱和NaCl溶液(50mL×1)萃取。有机相经减压蒸馏除去有机相溶剂后,残留物经硅胶板层析[展开剂:DCM:MeOH=20:1(v/v)]分离纯化得到化合物(0.12g),收率为83.0%。
ESI-HRMS m/z:426.2857[M+H]+
1H NMR(400MHz,Methanol-d4)δ:7.80(s,1H),7.41(d,J=1.6Hz,1H),7.39(d,J=1.8Hz,1H),7.31(d,J=2.0Hz,1H),7.28(d,J=6.3Hz,1H),7.22–7.17(m,1H),5.42–5.25(m,1H),4.60(p,J=6.8Hz,1H),3.91–3.77(m,2H),1.55(dd,J=19.2,6.9Hz,12H),1.41(m,J=7.1Hz,2H),1.45(m,J=7.0Hz,2H),1.37–1.25(m,2H),1.22–1.10(m,4H),0.82(s,3H).
除了用相应反应化合物替换实施例10中(2,4-二甲基苯基)甲醇,以和实施例10相同的方法合成以下化合物:
/>
实施例16:(2R)-2-((4-((4,6-二甲基吡啶-3-基)甲基)胺)-9-乙基-9H-嘌呤-2-基)胺)-5-甲基-1-己醇
步骤1:N-((4,6-二甲基吡啶-3-基)甲基)-9-乙基-2-氟-9H-嘌呤-6-胺(i)的制备
向装有N-((4,6-二甲基吡啶-3-基)甲基)-9-乙基-2-氟-9H-嘌呤-6-胺(0.10g,0.35mmol,1.0eq)的三颈瓶中加入无水DMF(5mL),再加入无水K2CO3(0.49g,3.50mmol,10.0eq),N2保护下于室温缓慢加入乙基溴(0.26g,2.40mmol,6.9eq),室温反应24h。TLC点板监测原料反应完全,加水(50mL×1)加EA(50mL×3)萃取,合并有机相,饱和NaCl溶液(50mL×3)萃取。无水Na2SO4干燥过夜,减压蒸除溶剂后得到黄色油状液体i(0.10g),收率为97.8%。ESI-HRMS m/z:301.1541[M+H]+
步骤2:(2R)-2-((4-((4,6-二甲基吡啶-3-基)甲基)胺)-9-乙基-9H-嘌呤-2-基)胺)-5-甲基-1-己醇的制备
向装有i(0.10g,0.33mmol,1.0eq)的微波反应瓶中加入1,2-丙二醇(2mL)溶清,再加入DIPEA(0.20g,1.34mmol,4.0eq)做碱,最后加入(R)-4-胺-5-甲基-1-己醇(0.05g,0.50mmol,1.5eq)。放入微波反应器中,设置反应温度为150℃,反应20min。TLC点板监测发现原料I反应完全,加水(50mL×1)加EA(50mL×3)萃取,合并有机相,饱和NaCl溶液(50mL×1)萃取。有机相经减压蒸馏除去有机相溶剂后,残留物经硅胶板层析[展开剂:DCM:MeOH=20:1(v/v)]分离纯化得到化合物(0.12g),收率为90.1%。
ESI-HRMS m/z:412.2813[M+H]+
1H NMR(400MHz,Methanol-d4)δ:8.30(s,1H),7.70(s,1H),7.09(s,1H),4.73(q,J=15.4Hz,2H),4.07(q,J=7.3Hz,2H),3.91(dt,J=6.5,5.2Hz,1H),3.79(d,J=6.0Hz,1H),3.76(d,J=6.0Hz,1H),3.72–3.56(m,2H),2.44(d,J=4.8Hz,3H),2.37(s,3H),1.98(dq,J=13.5,6.7Hz,1H),1.42(t,J=7.3Hz,3H),1.41(m,J=7.1Hz,2H),1.45(m,J=7.0Hz,2H),1.37–1.21(m,1H),0.94(dd,J=11.5,6.8Hz,6H).
除了用相应反应化合物替换实施例16中乙基溴,以和实施例16相同的方法合成以下化合物:
实施例18:激酶测定测量CDK2-cyclinE抑制
通过CDK2-cyclinE酶测定来确定IC50值。该测定包含两个步骤:酶促反应和检测步骤。首先,将CDK2-cyclinE蛋白、不同浓度的待测化合物、作为底物蛋白的p53和三磷酸腺苷(ATP)的混合物在测定缓冲液中温育。CDK2在Thr160和其他残基处磷酸化肽底物。然后使用特异性抗体和TR-FRET测定技术检测磷酸化肽底物的量。
详细说明:CDK2-cyclinE测定作为基于TR-FRET-(HTRFTM,Cisbio Bioassays)的384孔测定进行。在第一步中,将纯化的人CDK2-cyclinE在22℃下在含有不同浓度的测试化合物或不含测试化合物(作为阴性对照)的测定缓冲液中温育15分钟。测定缓冲液含有25mMHEPES pH 8.0,10mM Mg(CH3COO)2,1mM MnCl2,0.1% BSA,0.01%35和5mM二硫苏糖醇(DTT)。Echo 555(Labcyte)用于分配化合物溶液。然后,在第二步中,加入纯化的肽底物和ATP,并将反应混合物在22℃温育25-35分钟(通常25分钟)。药理学相关的测定体积为5μl。在反应混合物的温育期间,测定中的最终浓度为0.3-0.5nM(通常为0.3nM)CDK2-cyclinE,50nM肽底物和0.5μM ATP。通过加入EDTA终止酶促反应。通过使用能够实现FRET的特异性抗体[标记有荧光团铺(Eu)作为供体和d2作为受体(CisbioBioassays)]检测由于在ATP存在下的ATR介导的反应丽产生的磷酸化肽底物。为此目的,将2μl含有抗体的终止溶液(12.5mMHEPES pH 8.0,125mM EDTA,30mM氧化纳,300mM氟化钾,0.006% Tween-20,0.005%/>35,0.21nM抗磷酸化-p53(Ser15)-Eu抗体,15nM抗cmyc-d2抗体)加入到反应混合物中。在信号发展2小时后,使用TRF模式和激光激发在EnVision(PerkinElmer)酶标仪中分析板。在340nm激发供体铕后,测量受体d2在665nm处以及在615nm处从供体Eu发射的荧光。磷酸化肽底物的量与在665nm和615nm下发射光的量的比率(即相对荧光单位(rfu)的比率)直接成正比。使用XLFit Excel软件处理数据。特别地,通过使用非线性回归分析将剂量-响应曲线拟合到数据点,以常规方式确定IC50值。
实验结果显示在表1:
表1本发明实施例以及参照化合物(商购Seliciclib(CYC-202))活性测定的IC50(nM)数据
实施例19:细胞抗增殖活性测定
MV4-11细胞接种密度为每毫升1×105个,96孔板中细胞悬浮液(100μL),加入稀释成不同浓度的待测化合物(150μL),同时设置空白对照和阴性对照,于培养箱中培养72h。加入CCK-8溶液(10μL),于培养箱中培养4h,振板后用酶标仪在450nM下读取吸光值。
采用GraphPad Prism 5软件计算不同浓度下的抑制率,根据抑制率曲线拟合成对应的函数,计算IC50值。
计算公式:细胞生长抑制率%=1-(实验孔吸光值-空白吸光值)/(阴性对照吸光值-空白吸光值)×100%
在表2中显示了针对本发明的实施例测定的数据以及针对Fadraciclib获得的数据:
表2本发明的实施例以及参照化合物Seliciclib的MV4-11细胞抗增殖活性实验数据
其中n=实验重复的次数
这显示除实施例7、实施例9和实施例10,其他均具有比Seliciclib显著较优的效价。实施例1、实施例14、实施例16和实施例17具有低于纳摩尔级别的优于Seliciclib的抗增殖活性。
实施例20:使用人体肝脏微粒体进行化合物稳定性的评价
将实施例化合物的肝微粒体酶稳定性与Seliciclib进行比较。
测定系统:本发明化合物的代谢稳定性利用由男女混合的肝脏微粒体用1mMNADPH进行试验。样品使用质谱仪进行分析。将HRMS用于确定峰面积响应比率(对应于试验化合物或对照物的峰面积除以分析内标的峰面积)而不运行标准曲线。为了检测到所有的可能代谢物,在适当的m/z范围内进行HRMS扫描。
测定条件:该测定用一次孵育(N=1)进行。将试验化合物在37℃下在含有0.5毫克/毫升肝脏微粒体蛋白的缓冲液中孵育。通过加入辅因子引发反应,并于0、2、4、8、16、24、36、48小时取样,平行孵育阳性对照物(5μM睾丸素)并于0、2、4、8、16、24、36、48小时取样。
测定质量控制:平行进行对照化合物睾丸素以证实(肝脏)微粒体的酶活性。最终时间点后,利用荧光测定法来确认NADPH添加到反应混合物中。对照物的T1/2满足可接受的内标。
分析方法:
液相色谱柱:Thermo BDS Hypersil C18 30X2.0mm,3μm,具有保护柱M.P.,缓冲液:25mM甲酸接缓冲液,pH 3.5;
水相(A):90%水,10%缓冲液;
有机相(B):90%乙腈,10%缓冲液;
流速:300微升/分钟
自动进样器:注射体积10微升
梯度程序参见表3。
表3梯度程序
时间(分钟) | %A | %B |
0.0 | 100 | 0 |
1.5 | 0 | 100 |
2.0 | 0 | 100 |
2.1 | 100 | 0 |
3.5 | 100 | 0 |
通过使用人体肝微粒体,如本发明中所述实施例1-12表现出大于20小时的代谢半衰期,实施例13-17表现出介于18-24小时的代谢半衰期,略大于对比Fadraciclib(CYC-065)的15小时的代谢半衰期。相对较长的代谢半衰期使得本发明相对于Seliciclib(CYC-202)具有降低医疗剂量和扩大给药时间间隔的潜能。
以上所提供的实施例并非用以限制本发明所涵盖的范围,所描述的步骤也不是用以限制其执行顺序。本领域技术人员结合现有公知常识对本发明做显而易见的改进,亦落入本发明权利要求书所界定的保护范围之内。
Claims (10)
1.一种具有通式(I)的9H嘌呤类化合物或其药学上可接受的盐:
其中:
R1选自:其中,R3和R4各自独立地为氢或C1-8烷基(其中包含不同光学异构构型,分为S或R构型),或者R3和R4与其所连接的原子一起形成含0-3个杂原子的4-6元环,杂原子为O或N;R5和R6各自独立选自氢、C1-8烷基、三氟甲基、C3-6环烷基(其中包含不同光学异构构型,分为S或R构型),或者R5和R6与其所连接的原子形成含有一个O和0-2个杂原子的4-6元环或内酯环,杂原子为O或S;R7和R8各自独立选自氢、C1-8烷基,或者R7和R8与其所连接的杂原子一起形成含有0-3个杂原子的3-6元环,杂原子为O或S;
n1为2-4;n2为0-3;
R2选自:其中,X1、X5和X9各自独立地为CH2、NH或O;X2、X3、X4、X6、X7和X8各自独立地为CH或N;R为H、C1-3烷基;R9和R10选自氢、C1-3烷基、含1-2个N原子的含氮芳杂环或脂杂环、NR’R”或NHCOR”’,R’、R”、R”’各自独立地选自氢或甲基;R11和R12各自独立地为氢、卤素、C1-3烷基,或者R11和R12与其所连接的原子一起形成含有0-3个杂原子的饱和3-6元环,杂原子为O或N;R13为氢、卤素、C1-3烷基或C5-6环烷基、其中,X10和X11各自独立地为CH或N,R16为C1-5烷基或含有0-3个杂原子的饱和4-6元环,杂原子为O或N;R14为氢、卤素、C1-3烷基或C5-6环烷基;R15为氢、卤素、C1-3烷基、含有0-3个杂原子的饱和4-6元环;
R17选自:其中,R18、R19各自独立地为H、C1-3烷基,或R18和R19与其所连接的原子一起形成C3-6环烷基;R20和R21为C1-3烷基;R22为氢或C1-2烷基。
2.根据权利要求1所述的9H嘌呤类化合物或其药学上可接受的盐,其特征在于,所述的药学上可接受的盐包括如下任意一种:乙酸盐、己二酸盐、藻酸盐、精氨酸盐、天冬氨酸盐、苯甲酸盐、苯磺酸盐、硫酸氢盐、亚硫酸氢盐、溴化物、丁酸盐、樟脑酸盐、樟脑磺酸盐、辛酸盐、氯苯甲酸盐、柠檬酸盐、环戊烷丙酸盐、双葡萄糖酸盐、磷酸二氢盐、二硝基苯甲酸盐、十二烷基硫酸盐、乙磺酸盐、富马酸盐、甲酸盐、粘酸盐、半乳糖醛酸盐、葡萄糖庚酸盐、葡萄糖酸盐、谷氨酸盐、甘油磷酸盐、半琥珀酸盐、半硫酸盐、庚酸盐、己酸盐、马尿酸盐、盐酸盐、氢溴酸盐、氢碘酸盐、2-羟基乙磺酸盐、碘化物、羟乙基磺酸盐、异丁酸盐、乳酸盐、手L糖酸盐、苹果酸盐、马来酸盐、丙二酸盐、扁桃酸盐、偏磷酸盐、甲磺酸盐、甲基苯甲酸盐、磷酸一氢盐、2-萘磺酸盐、烟酸盐、硝酸盐、草酸盐、油酸盐、棕榈酸盐、果胶酸盐、过硫酸盐、苯乙酸盐、3-苯基丙酸盐、磷酸盐、膦酸盐、邻苯二甲酸盐。
3.权利要求1或2所述的9H嘌呤类化合物或其药学上可接受的盐在制备用于预防或治疗对抑制CDK2敏感的肿瘤药物中的用途。
4.一种药物组合物,其特征在于,包含权利要求1或2所述的9H嘌呤类化合物或其药学上可接受的盐。
5.一种用于治疗和/或预防癌症的药物,其特征在于,包含权利要求1或2所述的9H嘌呤类化合物或其药学上可接受的盐;所述癌症包括结直肠癌、非小细胞肺癌、膀胱癌、基底样乳腺癌、胰腺癌。
6.一种用于治疗和/或预防骨髓增生异常综合征的药物,其特征在于,包含权利要求1或2所述的9H嘌呤类化合物或其药学上可接受的盐。
7.一种用于治疗和/或预防B细胞慢性淋巴性白血病或者急性髓性白血病的药物,其特征在于,包含权利要求1或2所述的9H嘌呤类化合物或其药学上可接受的盐。
8.一种用于治疗和/或预防细菌以及HIV-1病毒感染的药物,其特征在于,包含权利要求1或2所述的9H嘌呤类化合物或其药学上可接受的盐。
9.根据权利要求4所述的药物组合物、或者权利要求5-8任一项所述的药物,其特征在于,组成中还包含药用辅料;药用辅料包括如下任意一种或多种:溶剂、抛射剂、增溶剂、助溶剂、乳化剂、着色剂、黏合剂、崩解剂、填充剂、润滑剂、润湿剂、渗透压调节剂、稳定剂、助流剂、矫味剂、防腐剂、助悬剂、包衣材料、芳香剂、抗黏合剂、整合剂、渗透促进剂、pH值调节剂、缓冲剂、增塑剂、表面活性剂、发泡剂、消泡剂、增稠剂、包合剂、保湿剂、絮凝剂与反絮凝剂、助滤剂以及释放阻滞剂。
10.根据权利要求4所述的药物组合物、或者权利要求5-8任一项所述的药物,其特征在于,组成中还包含药用载体;药物载体选自微囊、微球、纳米粒和脂质体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310676552.3A CN116813621A (zh) | 2023-06-08 | 2023-06-08 | 9h嘌呤类化合物及其药物组合物和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310676552.3A CN116813621A (zh) | 2023-06-08 | 2023-06-08 | 9h嘌呤类化合物及其药物组合物和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116813621A true CN116813621A (zh) | 2023-09-29 |
Family
ID=88111936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310676552.3A Pending CN116813621A (zh) | 2023-06-08 | 2023-06-08 | 9h嘌呤类化合物及其药物组合物和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116813621A (zh) |
-
2023
- 2023-06-08 CN CN202310676552.3A patent/CN116813621A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6959248B2 (ja) | 癌治療用の4,6−ジヒドロピロロ[3,4−c]ピラゾール−5(1H)−カルボニトリル誘導体 | |
AU2007316417B2 (en) | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors | |
RU2394825C2 (ru) | Пирролопиразины, пригодные в качестве ингибиторов киназы аврора а | |
US8557818B2 (en) | Compounds useful as protein kinase inhibitors | |
CA2939219C (en) | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | |
EP3398950B1 (en) | Novel kinase inhibitor against wild-type egfr and mutated egfr | |
US9956220B2 (en) | Imidazo-pyridazine derivatives as casein kinase 1 δ/ϵ inhibitors | |
CA2494127A1 (en) | Pyrimido compounds having antiproliferative activity | |
EP2896620A1 (en) | Alkynyl heteroaromatic ring compound and application thereof | |
JP2010505859A (ja) | タンパク質キナーゼ阻害剤およびそれを使用するための方法 | |
JP6267231B2 (ja) | カゼインキナーゼ1δ/ε阻害剤としての新規な置換イミダゾール | |
NO332005B1 (no) | Nye pyridopyraziner, anvendelse derav, medikament inneholdende minst en slik forbindelse og fremgangsmate for fremstilling av et slikt medikament | |
AU2008221278A1 (en) | Pyrimidine-2,4-diamine derivatives and their use as JAK2 kinase inhibitors | |
US10562888B2 (en) | Crystalline FGFR4 inhibitor compound and uses thereof | |
JP2007513172A (ja) | 複素環式プロテインキナーゼインヒビターおよびその使用 | |
JP2014513078A (ja) | パーキンソン病の治療方法及び治療用組成物 | |
CN111032630B (zh) | 一种化合物,其药物组合物及其用途及应用 | |
ES2709003T3 (es) | Compuestos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrilo y su uso terapéutico | |
KR102288246B1 (ko) | 라파마이신 신호전달 경로 저해제의 기계적 표적 및 이의 치료학적 적용 | |
CN115490671A (zh) | Parp7抑制剂及其制备方法 | |
CN116813621A (zh) | 9h嘌呤类化合物及其药物组合物和用途 | |
AU2018337138B2 (en) | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | |
TWI692476B (zh) | 環丁基-咪唑啶酮化合物 | |
CN112707907B (zh) | 嘌呤衍生物及其中间体与制备抗癌症药物的应用 | |
WO2023141866A1 (en) | Pyrazolopyrimidines as modulators of spermine oxidase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |